Lancid, 30 mg capsules 30 pcs

Lancid is an antiulcer.

Inhibits H⁺ – K⁺ATPase (proton pump) of parietal cells, blocks the terminal stage of hydrochloric acid formation, suppresses basal and stimulated secretion.

Pharmacodynamics

With high lipophilicity, easily penetrates into the parietal cells of the stomach, concentrates in them, has cytoprotective effect, increases bicarbonate secretion. Inhibition of hydrochloric acid formation at a dose of 30 mg is 80-97%. It does not affect the motility of the gastrointestinal tract. The inhibitory effect increases in the first four days of use. Secretory activity is restored in 3-4 days after discontinuation of the drug.

Pharmacokinetics

Absorption is high. C_max after oral administration at a dose of 30 mg is reached in 1.5-2.2 h and is 0.75-1.15 mg/L. Binding to plasma proteins is 98%. T_1/2 is 1.3-1.7 h (increases with impaired renal function and in old age). It is actively metabolized during primary passage through the liver. It is excreted by the kidneys as metabolites (14-23%) and by the intestine.

Indications

Gastric and duodenal ulcer, reflux esophagitis, erosive ulcers of the stomach and duodenum against the background of NSAID use or associated with Helicobacter pylori (in the complex therapy), stress ulcers, Zollinger-Ellison syndrome.

Active ingredient

Composition

1 capsule contains:

The active ingredient:

Lansoprazole – 15 mg or 30 mg.

Composition of capsule containing lansoprazole – 30 mg (body):

Gelatin – 38.9575 mg, sodium lauryl sulfate – 0.0376 mg, propyl parahydroxybenzoate – 0.37(30 mg. methyl parahydroxybenzoate – 0.0940 mg, titanium dioxide – 0.7120 mg, crimson dye [Ponceau 4R] – 0.0078 mg. water – 6.8150 mg.

Composition of the capsule containing lansoprazole – 30 mg (cap):

Gelatin – 24.0376 mg. sodium lauryl sulfate – 0.0232 mg, propyl parahydroxybenzoate – 0.0580 mg, methyl parahydroxybenzoate – 0.2320 mg, titanium dioxide – 0.4393 mg, crimson dye [Ponzo 4R]- 0.0048 mg. water – 4.2050 mg.

The composition of the black ink: ethanol – 29-33%, isopropanol – 9-12%, butanol – 4-7%, shellac – 24-28%, iron oxide black dye – 24-28%. water ammonia – 1-3%, propylene glycol 0,5-2%.

How to take, the dosage

In the morning, before a meal. Capsules should be swallowed whole without chewing.

Duodenal ulcer (acute stage): 30 mg/d for 2-4 weeks. (in resistant cases – up to 60 mg/day).

Peptic ulcer disease (acute stage) and erosive ulcerative esophagitis: 30-60 mg/d for 4-8 weeks.

Erotic ulcerative lesions of the gastrointestinal tract against NSAID use: 30 mg/day for 4-8 weeks.

Eradication of Helicobacter pylori: 30 mg 2 times daily for 10-14 days in combination with antibacterial agents.

Antiretroviral treatment of gastric and duodenal ulcer: 30 mg/day.

Antiretroviral treatment of reflux esophagitis: 30 mg/d for a long time (up to 6 months).

Zollinger-Ellison syndrome: dose is adjusted individually until basal secretion level >10 mmol/h is reached.

Interaction

Delays elimination of drugs metabolized in the liver by microsomal oxidation (including diazepam, phenytoin, indirect coagulants). Antacids slow down and reduce absorption.

Special Instructions

Before treatment, it is necessary to rule out the presence of a malignant process in the upper gastrointestinal tract.

Contraindications

Hypersensitivity, hepatic and/or renal insufficiency, pregnancy, lactation, childhood.

Side effects

Nervous system and sensory organs: headache, dizziness, somnolence, in single cases – depression.

Gastrointestinal organs: diarrhea, abdominal pain, constipation.

Allergic reactions: skin rashes.

Respiratory system: rhinitis, pharyngitis.

Others: myalgia.

Pregnancy use

It is contraindicated. Breastfeeding should be stopped during treatment.

Similarities